IL311364A - Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers - Google Patents

Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

Info

Publication number
IL311364A
IL311364A IL311364A IL31136424A IL311364A IL 311364 A IL311364 A IL 311364A IL 311364 A IL311364 A IL 311364A IL 31136424 A IL31136424 A IL 31136424A IL 311364 A IL311364 A IL 311364A
Authority
IL
Israel
Prior art keywords
ovarian
cancers
treatment
receptor modulators
glucocorticoid receptor
Prior art date
Application number
IL311364A
Other languages
Hebrew (he)
Inventor
Stacie Shepherd
Joseph K Belanoff
Original Assignee
Corcept Therapeutics Inc
Stacie Shepherd
Joseph K Belanoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/050617 external-priority patent/WO2023043444A1/en
Application filed by Corcept Therapeutics Inc, Stacie Shepherd, Joseph K Belanoff filed Critical Corcept Therapeutics Inc
Publication of IL311364A publication Critical patent/IL311364A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL311364A 2021-09-16 2022-09-02 Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers IL311364A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163244825P 2021-09-16 2021-09-16
PCT/US2021/050617 WO2023043444A1 (en) 2021-09-16 2021-09-16 Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
US202263324873P 2022-03-29 2022-03-29
US202263345682P 2022-05-25 2022-05-25
PCT/US2022/042475 WO2023043632A1 (en) 2021-09-16 2022-09-02 Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

Publications (1)

Publication Number Publication Date
IL311364A true IL311364A (en) 2024-05-01

Family

ID=85603418

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311364A IL311364A (en) 2021-09-16 2022-09-02 Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers

Country Status (8)

Country Link
EP (1) EP4401734A1 (en)
JP (1) JP2024534456A (en)
KR (1) KR20240063962A (en)
AU (1) AU2022344984A1 (en)
CA (1) CA3230034A1 (en)
IL (1) IL311364A (en)
MX (1) MX2024003254A (en)
WO (1) WO2023043632A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2019200156A1 (en) * 2018-04-11 2019-10-17 Oric Pharmaceuticals, Inc. Solid forms and formulations comprising a glucocorticoid receptor antagonist and uses thereof
US11234971B2 (en) * 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists

Also Published As

Publication number Publication date
CA3230034A1 (en) 2023-03-23
KR20240063962A (en) 2024-05-10
JP2024534456A (en) 2024-09-20
WO2023043632A1 (en) 2023-03-23
AU2022344984A1 (en) 2024-03-14
MX2024003254A (en) 2024-04-03
EP4401734A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
IL265217A (en) Glucocorticoid receptor modulators to treat pancreatic cancer
IL269725B (en) Glucocorticoid receptor modulators to treat cervical cancer
IL268011A (en) Modulators of estrogen receptor proteolysis and associated methods of use
IL282257A (en) Androgen receptor modulators and methods for their use
EP3912714A4 (en) Uniform mixing device of chili raw material
GEP20217271B (en) Combination therapy for the treatment of cancer
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP3645040A4 (en) Use of anti-fam19a5 antibodies for treating cancers
IL269009A (en) Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors
MX2021015508A (en) Pyridine carbamates and their use as glun2b receptor modulators.
IL288859A (en) Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
IL272669A (en) Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
IL269607A (en) Mineral coated microparticles for sustained delivery of biologically active molecules
IL311364A (en) Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
IL287837A (en) Intermittent dosing of glucocorticoid receptor modulators for the treatment of ovarian and other cancers
SI3707143T1 (en) New analogs as androgen receptor and glucocorticoid receptor modulators
EP3592358A4 (en) Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
GB202219507D0 (en) Use of pyridoxal in preparation of drugs for treating ovarian cancer
IL289313A (en) Treatment of pain using allosteric modulator of trpv1
IL279182A (en) Conveying apparatus and method of conveying tampon applicators
IL274007A (en) Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
EP3880709A4 (en) Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
PL3801854T3 (en) Dispensing system for mixture of two components and static mixing nozzle therefor
IL274698A (en) Combinations of irs/stat3 dual modulators and anti pd-1/pd-l1 antibodies for treating cancer